Caxton Associates LP Decreases Holdings in DaVita Inc. (NYSE:DVA)

Caxton Associates LP reduced its position in DaVita Inc. (NYSE:DVA) by 35.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 7,260 shares of the company’s stock after selling 3,998 shares during the period. Caxton Associates LP’s holdings in DaVita were worth $1,086,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the business. United Capital Financial Advisors LLC grew its stake in DaVita by 2.6% during the 4th quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company’s stock worth $361,000 after buying an additional 62 shares during the last quarter. Freedom Investment Management Inc. grew its stake in shares of DaVita by 3.6% during the fourth quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company’s stock worth $268,000 after acquiring an additional 62 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of DaVita by 8.3% during the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company’s stock valued at $133,000 after acquiring an additional 68 shares in the last quarter. Impact Partnership Wealth LLC raised its position in shares of DaVita by 3.7% in the 4th quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company’s stock valued at $290,000 after purchasing an additional 70 shares during the last quarter. Finally, Contravisory Investment Management Inc. boosted its stake in DaVita by 1.2% in the 4th quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company’s stock worth $910,000 after purchasing an additional 73 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on DVA shares. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. Cowen restated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. Barclays boosted their price target on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 18th. Finally, StockNews.com raised DaVita from a “hold” rating to a “buy” rating in a report on Friday, April 25th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $166.33.

DaVita Stock Performance

NYSE DVA opened at $141.48 on Tuesday. DaVita Inc. has a fifty-two week low of $131.44 and a fifty-two week high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The firm has a market capitalization of $10.87 billion, a P/E ratio of 13.17, a PEG ratio of 1.07 and a beta of 1.14. The stock has a 50-day simple moving average of $145.95 and a two-hundred day simple moving average of $154.35.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, equities analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.